Equibles does not estimate personal net worth.
Get an email with a short summary when Cellectar Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get CLRB alertsChad Kolean is recorded as CFO at Cellectar Biosciences, Inc. (CLRB). The newest filing on record that lists Chad Kolean as CFO at Cellectar Biosciences, Inc. (CLRB) is dated May 28, 2026. The proxy statement of Cellectar Biosciences, Inc. reports total compensation of $1,223,400 for Chad Kolean in fiscal 2024, including a base salary of $425,000. Disclosed compensation is on record for 3 fiscal years. Chad Kolean has spoken on 12 earnings calls across 1 company, most recently for Cellectar Biosciences, Inc. on August 13, 2026. Cellectar Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cellectar Biosciences, Inc. includes James Caruso (CEO and Board Member), James V. Caruso (CEO and Board Member), Douglas J. Swirsky (Chairman and Board Member) and 7 others.
“First, I will spend a couple of minutes on the financing that Jim mentioned. As he stated, the transaction provided the company with the current and anticipated future funding to support our strategy to obtain approval for IFOFC and I-131.”
“I'll address our financial results for the period ended March 31, 2026 and the recently completed financing that allows us to accelerate our development by both the CNI-131.”
“I'll address our financial results for the year ended December 31, 2025. We ended the year with cash and cash equivalents of $13.2 million, as compared to $23.3 million as of December 31, 2024.”
“Here are my comments on our financial results for the third quarter ended September 30, 2025. We ended the quarter with cash and cash equivalents of $12.6 million, which is compared to $23.3 million as of December 31, 2024.”
“I will address our financial results for the quarter ended June 30, 2025, beginning with our cash position. We ended the quarter with cash and cash equivalents of $11 million, which includes $2.3 million in net funds raised from the June financing, compared to $23.3 million as of December 31, 2024.”
Start not stated–present
Last confirmed May 28, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Cellectar Biosciences, Inc. (CLRB) | Chief Financial Officer | $425,000 | $1,223,400 |
| 2023 | Cellectar Biosciences, Inc. (CLRB) | Chief Financial Officer | $390,000 | $1,108,960 |
| 2022 | Cellectar Biosciences, Inc. (CLRB) | Chief Financial Officer | $290,417 | $461,643 |
